Purple Biotech (PPBT) Competitors

$2.70 -0.28 (-9.40%)

Closing price 04:00 PM Eastern

Extended Trading

$2.70 +0.00 (+0.11%)

As of 08:00 PM Eastern

PPBT vs. KTTA, QNCX, NCEL, ZIVO, and PASG

Should you buy Purple Biotech stock or one of its competitors? MarketBeat compares Purple Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Purple Biotech include Pasithea Therapeutics (KTTA), Quince Therapeutics (QNCX), NLS Pharmaceutics (NCEL), ZIVO Bioscience (ZIVO), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry.

How does Purple Biotech compare to Pasithea Therapeutics?

Purple Biotech (NASDAQ:PPBT) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Purple Biotech currently has a consensus target price of $30.00, suggesting a potential upside of 1,011.11%. Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 316.09%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Purple Biotech is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pasithea Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Purple Biotech had 10 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 12 mentions for Purple Biotech and 2 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.50 beat Purple Biotech's score of 0.92 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Purple Biotech	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

Purple Biotech has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

Pasithea Therapeutics' return on equity of -57.44% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-123.63%	-98.72%
Pasithea Therapeutics	N/A	-57.44%	-53.61%

9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Purple Biotech and Pasithea Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Purple Biotech compare to Quince Therapeutics?

Purple Biotech (NASDAQ:PPBT) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Purple Biotech is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A

Purple Biotech currently has a consensus target price of $30.00, indicating a potential upside of 1,011.11%. Quince Therapeutics has a consensus target price of $65.00, indicating a potential upside of 5,974.77%. Given Quince Therapeutics' higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than Purple Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Purple Biotech's return on equity of -123.63% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-123.63%	-98.72%
Quince Therapeutics	N/A	-372.88%	-67.99%

9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 3.0% of Purple Biotech shares are held by company insiders. Comparatively, 20.3% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Purple Biotech had 4 more articles in the media than Quince Therapeutics. MarketBeat recorded 12 mentions for Purple Biotech and 8 mentions for Quince Therapeutics. Purple Biotech's average media sentiment score of 0.92 beat Quince Therapeutics' score of 0.17 indicating that Purple Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Purple Biotech	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quince Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Purple Biotech has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

Summary

Quince Therapeutics beats Purple Biotech on 7 of the 13 factors compared between the two stocks.

How does Purple Biotech compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

9.6% of Purple Biotech shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 3.0% of Purple Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

Purple Biotech has a consensus price target of $30.00, indicating a potential upside of 1,011.11%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NLS Pharmaceutics' return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Purple Biotech	N/A	-123.63%	-98.72%

NLS Pharmaceutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

In the previous week, Purple Biotech had 12 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 12 mentions for Purple Biotech and 0 mentions for NLS Pharmaceutics. Purple Biotech's average media sentiment score of 0.92 beat NLS Pharmaceutics' score of 0.00 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
Purple Biotech	Positive

Summary

Purple Biotech beats NLS Pharmaceutics on 6 of the 11 factors compared between the two stocks.

How does Purple Biotech compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

ZIVO Bioscience's return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Purple Biotech	N/A	-123.63%	-98.72%

ZIVO Bioscience has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

In the previous week, Purple Biotech had 12 more articles in the media than ZIVO Bioscience. MarketBeat recorded 12 mentions for Purple Biotech and 0 mentions for ZIVO Bioscience. Purple Biotech's average media sentiment score of 0.92 beat ZIVO Bioscience's score of 0.00 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Purple Biotech	Positive

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 3.0% of Purple Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ZIVO Bioscience has higher revenue and earnings than Purple Biotech. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,063.54	-$7.78M	-$1.71	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

Purple Biotech has a consensus price target of $30.00, indicating a potential upside of 1,011.11%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Purple Biotech beats ZIVO Bioscience on 8 of the 14 factors compared between the two stocks.

How does Purple Biotech compare to Passage Bio?

Purple Biotech (NASDAQ:PPBT) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Passage Bio is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

In the previous week, Purple Biotech had 9 more articles in the media than Passage Bio. MarketBeat recorded 12 mentions for Purple Biotech and 3 mentions for Passage Bio. Purple Biotech's average media sentiment score of 0.92 beat Passage Bio's score of 0.33 indicating that Purple Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Purple Biotech	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Passage Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Purple Biotech's return on equity of -123.63% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-123.63%	-98.72%
Passage Bio	N/A	-150.88%	-59.78%

9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 4.9% of Passage Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Purple Biotech has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Purple Biotech currently has a consensus target price of $30.00, suggesting a potential upside of 1,011.11%. Passage Bio has a consensus target price of $13.25, suggesting a potential upside of 156.78%. Given Purple Biotech's higher probable upside, analysts clearly believe Purple Biotech is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Passage Bio beats Purple Biotech on 7 of the 13 factors compared between the two stocks.

Get Purple Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPBT vs. The Competition

Export

Metric	Purple Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.83M	$3.33B	$6.34B	$12.29B
Dividend Yield	N/A	2.29%	2.79%	5.33%
P/E Ratio	-0.14	18.53	21.09	25.40
Price / Sales	N/A	289.80	527.81	78.77
Price / Cash	N/A	129.82	44.13	56.13
Price / Book	0.36	6.90	9.99	7.01
Net Income	-$26.39M	$24.23M	$3.55B	$335.05M
7 Day Performance	-26.83%	0.59%	0.42%	-0.29%
1 Month Performance	-42.80%	-0.61%	-0.05%	1.15%
1 Year Performance	-88.61%	63.26%	35.06%	34.79%

Purple Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPBT Purple Biotech	3.2776 of 5 stars	$2.70 -9.4%	$30.00 +1,011.1%	-87.6%	$3.83M	N/A	N/A	20	Earnings Report Analyst Revision Gap Down
KTTA Pasithea Therapeutics	2.7168 of 5 stars	$0.70 -8.8%	$3.00 +327.0%	-26.3%	$17.52M	N/A	N/A	3	Positive News Earnings Report
QNCX Quince Therapeutics	2.27 of 5 stars	$1.07 +7.6%	$65.00 +5,974.8%	-89.4%	$17.44M	N/A	N/A	60
NCEL NLS Pharmaceutics	0.6804 of 5 stars	$3.18 +2.3%	N/A	-81.2%	$17.01M	N/A	N/A	6
ZIVO ZIVO Bioscience	N/A	$4.06 flat	N/A	-77.4%	$16.86M	$15.85K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPBT) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Purple Biotech (PPBT) Competitors

PPBT vs. KTTA, QNCX, NCEL, ZIVO, and PASG

How does Purple Biotech compare to Pasithea Therapeutics?

Summary

How does Purple Biotech compare to Quince Therapeutics?

Summary

How does Purple Biotech compare to NLS Pharmaceutics?

Summary

How does Purple Biotech compare to ZIVO Bioscience?

Summary

How does Purple Biotech compare to Passage Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Purple Biotech (PPBT) Competitors

PPBT vs. KTTA, QNCX, NCEL, ZIVO, and PASG

How does Purple Biotech compare to Pasithea Therapeutics?

Do analysts recommend PPBT or KTTA?

Does the media refer more to PPBT or KTTA?

Which has preferable valuation & earnings, PPBT or KTTA?

Which has more volatility and risk, PPBT or KTTA?

Is PPBT or KTTA more profitable?

Do institutionals & insiders hold more shares of PPBT or KTTA?

Summary

How does Purple Biotech compare to Quince Therapeutics?

Which has stronger valuation and earnings, PPBT or QNCX?

Do analysts rate PPBT or QNCX?

Is PPBT or QNCX more profitable?

Do insiders and institutionals believe in PPBT or QNCX?

Does the media refer more to PPBT or QNCX?

Which has more volatility and risk, PPBT or QNCX?

Summary

How does Purple Biotech compare to NLS Pharmaceutics?

Do insiders & institutionals hold more shares of NCEL or PPBT?

Which has stronger valuation and earnings, NCEL or PPBT?

Do analysts rate NCEL or PPBT?

Is NCEL or PPBT more profitable?

Which has more volatility & risk, NCEL or PPBT?

Does the media prefer NCEL or PPBT?

Summary

How does Purple Biotech compare to ZIVO Bioscience?

Is ZIVO or PPBT more profitable?

Which has more volatility & risk, ZIVO or PPBT?

Does the media prefer ZIVO or PPBT?

Do insiders and institutionals have more ownership in ZIVO or PPBT?

Which has stronger valuation & earnings, ZIVO or PPBT?

Do analysts prefer ZIVO or PPBT?

Summary

How does Purple Biotech compare to Passage Bio?

Which has better earnings and valuation, PPBT or PASG?

Does the media prefer PPBT or PASG?

Is PPBT or PASG more profitable?

Do institutionals and insiders hold more shares of PPBT or PASG?

Which has more volatility & risk, PPBT or PASG?

Do analysts recommend PPBT or PASG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools